0 146

Cited 2 times in

Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma.

Authors
 Ho Jin Shin  ;  Won Sik Lee  ;  Ho Seop Lee  ;  Hawk Kim  ;  Gyeong Won Lee  ;  Moo Kon Song  ;  Jin Seok Kim  ;  Ho Young Yhim  ;  Joo Seop Chung 
Citation
 LEUKEMIA & LYMPHOMA, Vol.55(11) : 2490-2496, 2014 
Journal Title
 LEUKEMIA & LYMPHOMA 
ISSN
 1042-8194 
Issue Date
2014
MeSH
Adolescent ; Adult ; Aged ; Antineoplastic Agents/therapeutic use ; Busulfan/administration & dosage ; Busulfan/therapeutic use* ; Carmustine/administration & dosage ; Cyclophosphamide/administration & dosage ; Cytarabine/administration & dosage ; Disease-Free Survival ; Etoposide/administration & dosage ; Female ; Humans ; Lymphoma, Large B-Cell, Diffuse/therapy* ; Male ; Melphalan/administration & dosage ; Middle Aged ; Remission Induction ; Retrospective Studies ; Stem Cell Transplantation/methods* ; Transplantation Conditioning/methods* ; Transplantation, Autologous ; Treatment Outcome ; Young Adult
Keywords
BEAM regimen ; Busulfan ; diffuse ; hematopoietic stem cell transplant ; large B-cell ; lymphoma
Abstract
We retrospectively examined the outcomes of 56 patients with diffuse large B-cell lymphoma (DLBCL) who underwent autologous stem cell transplant (ASCT) with BEAM/BEAC (carmustine, etoposide, cytarabine, melphalan/cyclophosphamide) or busulfan (Bu)-containing conditioning regimens. The Bu group had lower disease-related mortality and more frequent achievement of complete remission (CR) after ASCT from partial remission (PR) or refractory status before ASCT compared with the BEAM/BEAC group. The estimated 2-year EFS (59.3% vs. 15.0%) and overall survival (OS) (70.2% vs. 42.0%) in pre-ASCT rituximab-exposed patients with DLBCL were higher in the Bu group. In patients with high-risk DLBCL exposed to rituximab with first remission, the Bu group had better EFS (p = 0.004) and OS (p = 0.053) rates, while survival rates for relapsed/refractory patients did not differ between groups. Bu regimens are highly effective for preparing patients with DLBCL with previous exposure to rituximab for ASCT, especially in high-risk patients who achieved a first remission.
Full Text
http://www.tandfonline.com/doi/full/10.3109/10428194.2014.882504
DOI
10.3109/10428194.2014.882504
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/138795
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse